iamnero.blogg.se - 300 mcg to mg

#300 MCG TO MG FULL#

Use: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism Usual Pediatric Dose for HypothyroidismĠ to 3 months: 10 to 15 mcg/kg orally once a dayģ to 6 months: 8 to 10 mcg/kg orally once a dayĦ to 12 months: 6 to 8 mcg/kg orally once a dayġ to 5 years: 5 to 6 mcg/kg orally once a dayĦ to 12 years: 4 to 5 mcg/kg orally once a dayġ2 years or older and incomplete growth and puberty: 2 to 3 mcg/kg orally once a dayġ2 years or older with growth and puberty complete: 1.6 mcg/kg orally once a day

#300 MCG TO MG FULL#

Peak effect of a given dose may not be attained for 4 to 6 week full recovery dose s.Dosing should be individualized with consideration given to age, cardiovascular status, concomitant medical conditions, and the specific nature of condition follow clinical response and laboratory parameters closely as dose is adjusted.Maximum dose: 200 to 300 mcg/day (doses greater than 200 mcg/day are seldom needed doses greater than 300 mcg/day are rarely needed and may indicate poor compliance, malabsorption, drug interactions, or a combination of these factors) Maintenance dose: Full replacement doses may be less than 1 mcg/kg/day The relative bioavailability between oral and IV levothyroxine is estimated to be 48% to 74% due to individual differences, TSH levels should be measured and doses adjusted accordingly.Age, general physical condition, cardiac risk factors, severity and duration of myxedema coma should be considered when determining the initial and maintenance dosages.Maintenance dose: 50 to 100 mcg IV once a day until patient can tolerate oral therapy.Initial loading dose: 300 to 500 mcg IV once.Use: As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-ĭependent well-differentiated thyroid cancer. This drug is not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment may induce hyperthyroidism.

Patients with high-risk tumors may target a greater level of TSH suppression, however, this is not well defined.

A dose greater than 2 mcg/kg orally once a day is usually required to achieve this degree of suppression.

TSH levels should generally be suppressed to below 0.1 IU/L Use: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism Usual Adult Dose for TSH Suppression

Co-administered food and concomitant medications may significantly affect absorption take on an empty stomach and at least 4 hours before or after drugs known to interfere with levothyroxine absorption.

Not indicated for the treatment of hypothyroidism during the recovery phase of subacute thyroiditis.

Peak effect of a given dose may not be attained for 4 to 6 weeks.

Dose should be individualized with regular monitoring of clinical status and laboratory parameters.

Titrate until clinically euthyroid and serum free-T4 levels are restored to the upper half of the normal range.

Dosing as described above except serum free-T4 level will be used to monitor therapy serum TSH levels are not a reliable measure and should not be used.

Secondary (PITUITARY) OR Tertiary (HYPOTHALAMIC) Hypothyroidism: MAXIMUM dose: 200 to 300 mcg/day (doses greater than 200 mcg/day are seldom needed doses greater than 300 mcg/day are rarely needed and may indicate poor compliance, malabsorption, drug interactions, or a combination of these factors) MAINTENANCE DOSE: Approximately 1.6 mcg/kg/day is a full replacement dose

Adjust dose in increments of 12.5 to 25 mcg/day every 2 to 4 weeks until clinically euthyroid and TSH returns to normal.

Adjust dose at 6 to 8-weeks intervals until clinically euthyroid and TSH returns to normal.

Initial dose: 12.5 to 25 mcg orally once a day Individuals over 50 years and/or Patients with Cardiovascular Disease:

Adjust dose in 12.5 to 25 mcg increments every 4 to 6 weeks until clinically euthyroid and TSH returns to normal.

Initial dose: 1.6 mcg/kg orally once a day Primary Hypothyroidism: For otherwise healthy individuals in whom growth and puberty are complete:

Dosing should be individualized with consideration given to age, cardiovascular status, concomitant medical conditions (including pregnancy), and specific nature of condition follow clinical response and laboratory parameters closely as dose is adjusted: